Humanized Anti-CD4 Antibody for Immune Checkpoint Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy methods, such as immune checkpoint inhibitors, often cause severe side effects due to their non-specific attack on both cancer cells and normal cells, limiting their effectiveness and patient satisfaction.
Innovation Solution
The development of a humanized anti-CD4 antibody with high cytotoxic activity, which can be used in combination with immune checkpoint antibodies to reduce side effects and enhance cancer treatment efficacy by specifically targeting CD4-positive cells, thereby minimizing non-tumor-related deaths and improving survival rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint inhibitors are used to treat cancer, then therapeutic effects are achieved, but severe side effects occur due to non-specific attack on normal cells
Solution Approach 1:
The invention divides the treatment approach by combining immune checkpoint inhibitors with anti-CD4 antibodies, creating a segmented strategy where each agent targets specific aspects of the immune response. The anti-CD4 antibody specifically targets CD4-positive T cells that mediate autoimmune-like side effects, while the immune checkpoint inhibitor maintains anti-tumor activity, thus separating the therapeutic benefit from the harmful effects
Solution Approach 2:
The anti-CD4 antibody acts as an intermediary agent that selectively modulates the immune response by targeting CD4-positive T cells. This intermediary approach allows the immune checkpoint inhibitor to maintain its anti-tumor efficacy while the anti-CD4 antibody mediates protection against autoimmune-like side effects by suppressing overactivated T cells
2Reliability
If conventional carcinostatic drugs are used to directly target cancer cells, then tumor growth is inhibited, but heavy burdens and serious side effects are imposed on patients
Solution Approach 1:
The invention replaces the direct mechanical/cellular targeting approach of conventional carcinostatic drugs with an immunological approach. Instead of directly attacking cancer cells with cytotoxic drugs, the treatment harnesses the patient's own immune system through immune checkpoint inhibitors and anti-CD4 antibodies, substituting direct chemical warfare with biologically-mediated immunity that is more selective and has fewer off-target effects
Data Source
AI summary
Disclosed is a means for reducing side effects of an immune checkpoint regulator that is used as an anticancer drug or the like. A side-effect reducing agent according to the present invention comprises as an effective ingredient an anti-CD4 antibody having a high cytotoxic activity, or an anti-CD4 antibody or antigen-binding fragment thereof which antibody or fragment comprises a cytotoxic component bound thereto. The anti-CD4 antibody is a human-type chimeric antibody, humanized antibody or human antibody against human CD4. The immune checkpoint regulator may be, for example, an anti-PD-L1 antibody, an antagonistic anti-CTLA-4 antibody, or an agonistic anti-OX40 antibody.